Cedars-Sinai Medical Center | Smidt Heart Institute
Status and phase
Conditions
Treatments
About
This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for Neoadjuvant Therapy:
Inclusion Criteria for Adjuvant Therapy (TKI Cohorts and KRAS G12C cohort [if continuing on Divarasib]):
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
125 participants in 7 patient groups
Loading...
Central trial contact
Reference Study ID Number: ML41591 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal